BR112014015357A2 - método para a preparação de partículas de proteína precipitada amorfa - Google Patents
método para a preparação de partículas de proteína precipitada amorfaInfo
- Publication number
- BR112014015357A2 BR112014015357A2 BR112014015357A BR112014015357A BR112014015357A2 BR 112014015357 A2 BR112014015357 A2 BR 112014015357A2 BR 112014015357 A BR112014015357 A BR 112014015357A BR 112014015357 A BR112014015357 A BR 112014015357A BR 112014015357 A2 BR112014015357 A2 BR 112014015357A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- amorphous precipitated
- protein particles
- precipitated protein
- dry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201122408A GB201122408D0 (en) | 2011-12-23 | 2011-12-23 | Method for preparing dry protein formulations |
| PCT/GB2012/053265 WO2013093524A2 (en) | 2011-12-23 | 2012-12-24 | Method for preparing amorphous precipitated protein particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014015357A2 true BR112014015357A2 (pt) | 2017-07-11 |
Family
ID=45695047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014015357A BR112014015357A2 (pt) | 2011-12-23 | 2012-12-24 | método para a preparação de partículas de proteína precipitada amorfa |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140348852A1 (https=) |
| EP (1) | EP2793863B1 (https=) |
| JP (1) | JP2015500869A (https=) |
| BR (1) | BR112014015357A2 (https=) |
| CA (1) | CA2859288A1 (https=) |
| DK (1) | DK2793863T3 (https=) |
| GB (1) | GB201122408D0 (https=) |
| IN (1) | IN2014MN01377A (https=) |
| WO (1) | WO2013093524A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11174458B2 (en) * | 2007-04-23 | 2021-11-16 | Koligo Therapeutics, Inc. | Cell separation apparatus and methods of use |
| GB201313368D0 (en) * | 2013-07-26 | 2013-09-11 | Xstalbio Ltd | Novel Reconstitution devices |
| US11654112B2 (en) | 2016-11-22 | 2023-05-23 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| AU2018306303A1 (en) | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
| KR20200143449A (ko) * | 2018-04-16 | 2020-12-23 | 메르크 파텐트 게엠베하 | 메글루민 염을 사용하여 단백질을 포함하는 제형을 안정화시키는 방법 |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| WO2019226969A1 (en) | 2018-05-24 | 2019-11-28 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| EP3917500A2 (en) | 2019-01-31 | 2021-12-08 | Elektrofi, Inc. | Particle formation and morphology |
| KR102941878B1 (ko) * | 2019-02-05 | 2026-03-23 | 린디 바이오사이언시스, 아이엔씨. | 단리된 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법 |
| WO2021050953A1 (en) | 2019-09-13 | 2021-03-18 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| JP2023522627A (ja) | 2020-04-17 | 2023-05-31 | エレクトロフィ，インコーポレイテッド | 連続的な液滴形成及び脱水によって粒子を形成する方法 |
| CN115844752B (zh) * | 2022-11-02 | 2024-06-28 | 上海铂舍生物科技有限公司 | 一种5d超分子胶原蛋白及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0300427D0 (en) | 2003-01-09 | 2003-02-05 | Univ Strathclyde | Pharmaceutical composition |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
-
2011
- 2011-12-23 GB GB201122408A patent/GB201122408D0/en not_active Ceased
-
2012
- 2012-12-24 BR BR112014015357A patent/BR112014015357A2/pt not_active IP Right Cessation
- 2012-12-24 DK DK12816095.9T patent/DK2793863T3/en active
- 2012-12-24 CA CA2859288A patent/CA2859288A1/en not_active Abandoned
- 2012-12-24 IN IN1377MUN2014 patent/IN2014MN01377A/en unknown
- 2012-12-24 WO PCT/GB2012/053265 patent/WO2013093524A2/en not_active Ceased
- 2012-12-24 JP JP2014548209A patent/JP2015500869A/ja not_active Withdrawn
- 2012-12-24 US US14/367,088 patent/US20140348852A1/en not_active Abandoned
- 2012-12-24 EP EP12816095.9A patent/EP2793863B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| GB201122408D0 (en) | 2012-02-08 |
| EP2793863A2 (en) | 2014-10-29 |
| WO2013093524A3 (en) | 2013-08-15 |
| JP2015500869A (ja) | 2015-01-08 |
| CA2859288A1 (en) | 2013-06-27 |
| EP2793863B1 (en) | 2018-07-25 |
| DK2793863T3 (en) | 2018-11-12 |
| US20140348852A1 (en) | 2014-11-27 |
| WO2013093524A2 (en) | 2013-06-27 |
| IN2014MN01377A (https=) | 2015-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014015357A2 (pt) | método para a preparação de partículas de proteína precipitada amorfa | |
| BR112013020767A2 (pt) | composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo | |
| CY1118601T1 (el) | Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων | |
| BR112013028449A2 (pt) | composições compreendendo partículas de hidrogel | |
| BR112013020513A2 (pt) | adoçante stevia altamente solúvel | |
| NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
| BR112015013129A2 (pt) | métodos e materiais para a biossíntese de compostos mogrosida | |
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| PH12013502284A1 (en) | Protein-active agent conjugates and method for preparing the same | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| SG195086A1 (en) | Compounds containing hydrido-tricyano-borate anions | |
| DOP2014000297A (es) | Método para producir iduronato-2-sulfatasa recombinante | |
| BR112014002173A2 (pt) | proteínas purificadas | |
| MY155330A (en) | Methods for salt production | |
| IN2015DN02381A (https=) | ||
| BR112013028607A2 (pt) | composições sólidas contendo éter glicólico e água | |
| PH12013501549A1 (en) | Oral care compositions | |
| MY173722A (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome | |
| IN2015DN04074A (https=) | ||
| TWD155682S (zh) | 椅子（二） | |
| BR112013023354A2 (pt) | vacina para rinite equina | |
| AU2012201606B2 (en) | Crystalline levofolinic acid and process for its preparation | |
| IN2014DN10135A (https=) | ||
| WO2013095994A3 (en) | Transparent aqueous fragrance microemulsions | |
| BR112014013723A8 (pt) | formas cristalinas da [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida do ácido 2-(2-metil-amino-pirimidin-4-il)-1h-indol-5-carboxílico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |